No black box warning on record for Bleomycin

As of the latest FDA labeling reviewed, Bleomycin (BLEOMYCIN SULFATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Bleomycin medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Patients receiving bleomycin must be observed carefully and frequently during and after therapy. It should be used with extreme caution in patients with significant impairment of renal function or compromised pulmonary function. Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis and

No black box warning on record for Bleomycin

Other warnings & precautions

WARNINGS Patients receiving bleomycin must be observed carefully and frequently during and after therapy. It should be used with extreme caution in patients with significant impairment of renal function or compromised pulmonary function. Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis and

Bleomycin Black Box Warning

No black box warning on record for Bleomycin

Other warnings & precautions

Bleomycin Black Box Warning

No black box warning on record for Bleomycin

Other warnings & precautions